Evidence map›Paper›PMID 40250631›Full record

ArticleAntiviral research2025

Inhibition of MAPK signaling suppresses cytomegalovirus reactivation in CD34

Vargab Baruah, Benjamin A Krishna, Michael C Kelly, Xu Qi, Christine M O'Connor

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Mechanisms and Determinants of CMV Reactivation in Kidney Transplantation.International journal of molecular sciences · 2026
    Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Vargab BaruahInfection Biology, Sheikha Fatima Bint Mubarak Global Center for Pathogen and Human Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA; Case Comprehensive Cancer Center, Cleveland, OH, 44106, USA. Electronic address: baruahv@ccf.org.
Benjamin A KrishnaInfection Biology, Sheikha Fatima Bint Mubarak Global Center for Pathogen and Human Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA; Case Comprehensive Cancer Center, Cleveland, OH, 44106, USA. Electronic address: back2@cam.ac.uk.
Michael C KellyInfection Biology, Sheikha Fatima Bint Mubarak Global Center for Pathogen and Human Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA; Case Comprehensive Cancer Center, Cleveland, OH, 44106, USA. Electronic address: kellym25@ccf.org.
Xu QiInfection Biology, Sheikha Fatima Bint Mubarak Global Center for Pathogen and Human Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA; Case Comprehensive Cancer Center, Cleveland, OH, 44106, USA. Electronic address: qix2@ccf.org.
Christine M O'ConnorInfection Biology, Sheikha Fatima Bint Mubarak Global Center for Pathogen and Human Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA; Case Comprehensive Cancer Center, Cleveland, OH, 44106, USA; Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine, Cleveland Clinic, Cleveland, OH, 44195, USA. Electronic address: oconnoc6@ccf.org.

Funding

Manipulation of host factors that promote HCMV latencyR01AI150931 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI O'CONNOR, CHRISTINE M · 2021 to 2025
$2.4M
HCMV GPCR functions during latency and reactivationR01AI153348 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI O'CONNOR, CHRISTINE M · 2021 to 2025
$2.2M
NIAID NIH HHS R01 AI150931NIAID NIH HHS R01 AI153348
6 · The paper itself

Abstract

Reactivation of latent human cytomegalovirus (CMV) can lead to severe complications in individuals with dysregulated immune systems. While antiviral therapies for CMV are approved, these compounds are limited by their toxicity and inability to specifically target the latent reservoir or prevent reactivation. Herein we show that CMV reactivation in Kasumi-3 cells, a CD34

Indexed as

CytomegalovirusMAP Kinase Signaling SystemMitogen-Activated Protein KinasesVirus ActivationAntigens, CD34Antiviral AgentsCell LineCytomegalovirus InfectionsHematopoietic Stem CellsHumansProtein Kinase InhibitorsVirus LatencyAntigens, CD34Antiviral AgentsMitogen-Activated Protein KinasesProtein Kinase InhibitorsCMVCytomegalovirusLatencyMAPKReactivationUS28

Identifiers

PMID40250631
PMCPMC12908883

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.